rituximab therapy reduces organ-specific t cell responses and ameliorates experimental autoimmune encephalomyelitis美罗华治疗实验性自身免疫性脑脊髓炎减少瀑特异性t细胞的反应和改善.pdfVIP

下载本文档

0
0
约3.86万字
约 6页
2017-10-13 发布于上海
举报
版权申诉

rituximab therapy reduces organ-specific t cell responses and ameliorates experimental autoimmune encephalomyelitis美罗华治疗实验性自身免疫性脑脊髓炎减少瀑特异性t细胞的反应和改善.pdf

1、本文档共6页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

rituximab therapy reduces organ-specific t cell responses and ameliorates experimental autoimmune encephalomyelitis美罗华治疗实验性自身免疫性脑脊髓炎减少瀑特异性t细胞的反应和改善

Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis 1,2 1 1 1 1 Nancy L. Monson , Petra Cravens , Rehana Hussain , Christopher T. Harp , Matthew Cummings , Maria 1 1 1 3 4 5 de Pilar Martin , Li-Hong Ben , Julie Do , Jeri-Anne Lyons , Amy Lovette-Racke , Anne H. Cross , 6 ¨ 1,7 8 1,2 Michael K. Racke , Olaf Stuve , Mark Shlomchik , Todd N. Eagar * 1 Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 2 Department of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America, 3 Health Sciences, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, United States of America, 4 Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America, 5 Department of Neurology, Washington University, St. Louis, Missouri, United States of America, 6 Department of Neurology, The Ohio State University, Columbus, Ohio, United States of America, 7 Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas, United States of America, 8 Laboratory Medicine and Immunobiology, Yale University, New Haven, Connecticut, United States of America Abstract Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sc